Systematic review: Current evidence in non-alcoholic fatty liver disease lacks relevance to patients with advanced fibrosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 5, 2017, Pages 950-956

  Parker, Richard ^a   Hodson, James ^b   Rowe, Ian A C ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

non alcoholic fatty liver disease; non alcoholic steatohepatitis; systematic review

Indexed keywords

BODY MASS; EXTERNAL VALIDITY; HUMAN; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW; AGE; BIBLIOGRAPHIC DATABASE; CHI SQUARE DISTRIBUTION; COMORBIDITY; DIABETES MELLITUS; LIVER CIRRHOSIS; META ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PATIENT; RISK;

AGE FACTORS; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DATABASES, BIBLIOGRAPHIC; DIABETES MELLITUS; HUMANS; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBSERVATIONAL STUDIES AS TOPIC; PATIENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 85018682908     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13625     Document Type: Review

References (23)

1. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592–1609.
2. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of Hepatic Steatosis in an urban population in the United States: impact of ethnicity. hepatology 2004; 40: 1387–1395.
3. Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124–131.
4. Lazo M, Hernaez R, Bonekamp S et al. Non-alcoholic fatty liver disease and mortality among us adults: prospective cohort study. BMJ 2011; 343.
5. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113–121.
6. Ekstedt M, Hagström H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547–1554.
7. Musso G, Gambino R, Cassader M et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79–104.
8. Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. The Lancet. 2005; 365: 82–93.
9. Steg PG, López-Sendón J, De Sa EL et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007; 167: 68–73.
10. Travers J, Marsh S, Williams M et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007; 62: 219–223.
11. Travers J, Marsh S, Caldwell B et al. External validity of randomized controlled trials in COPD. Respir Med 2007; 101: 1313–1320.
12. Van Spall HGC, Toren A, Kiss A et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007; 297: 1233–1240.
13. Schulz KF, Altman DG, Moher D. Consort 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010; 8: 18.
14. Von Elm E, Altmans DG, Egger M et al. The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies. Int J Surg 2014; 12: 1495–1499.
15. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.
16. Mohanty SR, troy t, huo d et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50: 797–804.
17. Bambha K, Belt P, Abraham M et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012; 55: 769–780.
18. Raji A, Seely EW, Arky RA et al. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metabol 2001; 86: 5366–5371.
19. Sanyal AJ, Friedman SL, Mccullough AJ et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases – U.S. Food and Drug Administration joint workshop. Hepatology 2015; 61: 1392–1405.
20. Marcellin P, Gane E, Buti M et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis b: a 5-year open-label follow-up study. The Lancet 2013; 381: 468–475.
21. Ratziu V, Harrison SA, Francque S et al. Elafibranor, an agonist of the peroxisome proliferator− activated receptor− Î ± and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016; 150: 1147–1159. e5.
22. Sanyal AJ, Brunt EM, Kleiner DE et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344–353.
23. Armstrong MJ, Adams LA, Canbay A et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014; 59: 1174–1197.